Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Exelixis Inc (EXEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 7,965,048
  • Shares Outstanding, K 292,510
  • Annual Sales, $ 191,450 K
  • Annual Income, $ -70,220 K
  • 36-Month Beta 1.88
  • Price/Sales 41.24
  • Price/Cash Flow 0.00
  • Price/Book 65.88

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.08 +21.79%
on 06/28/17
28.14 -0.11%
on 07/24/17
+4.33 (+18.21%)
since 06/23/17
3-Month
18.03 +55.91%
on 05/30/17
28.14 -0.11%
on 07/24/17
+6.81 (+31.97%)
since 04/24/17
52-Week
8.58 +227.62%
on 07/26/16
28.14 -0.11%
on 07/24/17
+19.43 (+223.85%)
since 07/22/16

Most Recent Stories

More News
What's in the Cards for Exelixis (EXEL) in Q2 Earnings?

Exelixis, Inc.'s (EXEL) efforts to develop its pipeline and uptake in Cabometyx sales should be the key areas of focus when the company reports second-quarter results.

VRTX : 166.11 (+1.80%)
EXEL : 28.11 (+3.23%)
BMY : 55.60 (-0.09%)
ALXN : 130.74 (-0.80%)
Emergent Inks Agreement to Acquire Anthrax Drug Raxibacumab

Emergent's shares inched up post announcement of its deal inked with GlaxoSmithKline to acquire the latter's anthrax monoclonal antibody raxibacumab.

ENZ : 11.30 (-0.44%)
EBS : 35.94 (+0.08%)
EXEL : 28.11 (+3.23%)
GSK : 42.24 (-0.98%)
Exelixis Announces Settlement of Dispute with Genentech Regarding Companies' Collaboration Agreement for Cobimetinib

--- Cobimetinib's clinical development program includes three ongoing or planned phase 3 pivotal trials -

EXEL : 28.11 (+3.23%)
Vertex (VRTX) Triple Combination CF Studies Data Positive

Vertex announced positive data from three studies evaluating three different triple combination regimens. These demonstrated pronounced improvements in lung function in CF patients.

ENZ : 11.30 (-0.44%)
CORT : 12.53 (-3.39%)
VRTX : 166.11 (+1.80%)
EXEL : 28.11 (+3.23%)
Valeant (VRX) To Sell Obagi for $190 Million to Lower Debt

Valeant (VRX) has decided to sell Obagi Medical for $190 million and use the proceeds for reducing down debt.

ENZ : 11.30 (-0.44%)
EXEL : 28.11 (+3.23%)
VRX : 17.54 (+0.23%)
SNY : 47.71 (unch)
Agenus (AGEN) Catches Eye: Stock Moves Up 8.7% in Session

Agenus Inc. (AGEN) moved big last session, as its shares rose over 8% on the day.

AGEN : 5.37 (+6.34%)
EXEL : 28.11 (+3.23%)
Exelixis Inc Shares Up 26.2% Since SmarTrend's Buy Recommendation (EXEL)

SmarTrend identified an Uptrend for Exelixis Inc (NASDAQ:EXEL) on June 19th, 2017 at $20.72. In approximately 4 weeks, Exelixis Inc has returned 26.24% as of today's recent price of $26.15.

EXEL : 28.11 (+3.23%)
SmarTrend Watching for Potential Rebound in Shares of Exelixis Inc After 1.01% Loss

Exelixis Inc (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $25.78 to a high of $26.52. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $26.03...

EXEL : 28.11 (+3.23%)
Exelixis to Release Second Quarter 2017 Financial Results on Wednesday, August 2, 2017

Exelixis, Inc. (NASDAQ:EXEL) announced today that its second quarter 2017 financial results will be released on Wednesday, August 2, 2017 after the markets close. At 5:00 p.m. EDT / 2:00...

EXEL : 28.11 (+3.23%)
Arena Announces Secondary Stock Worth $150M (revised)

Arena plans to offer and sell shares of its common stock worth $150 million, subject to customary closing conditions.

ENZ : 11.30 (-0.44%)
AZN : 33.85 (-0.59%)
ARNA : 24.34 (+1.21%)
EXEL : 28.11 (+3.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ' (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another...

See More

Support & Resistance

2nd Resistance Point 28.76
1st Resistance Point 28.43
Last Price 28.11
1st Support Level 27.49
2nd Support Level 26.88

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.